A Study of LAM-003 in Patients With Acute Myeloid Leukemia

O

OrphAI Therapeutics

Status and phase

Completed
Phase 1

Conditions

Oncology
Acute Myeloid Leukemia

Treatments

Drug: Open Label LAM-003

Study type

Interventional

Funder types

Industry

Identifiers

NCT03426605
LAM-003-HEM-CLN02

Details and patient eligibility

About

A Phase 1 Dose-Escalation Study of LAM-003 in Patients with Acute Myeloid Leukemia

Full description

This clinical trial is a Phase 1 study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of LAM-003 across a range of LAM-003 dose levels when administered to subjects with previously treated relapsed or refractory cute Myeloid Leukemia (AML). Subjects will self-administer oral LAM-003 either once or twice per day as long as they are safely benefitting from therapy. Cohorts of 3 to 6 subjects will be sequentially enrolled at progressively higher dose levels of LAM-003 using a standard 3+3 dose-escalation design. Based on the pattern of dose-limiting toxicities observed in the first 4 weeks of therapy, escalation will proceed to define a recommended LAM-003 dosing regimen.

Enrollment

17 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Men and women of age ≥18 years.
  2. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
  3. Presence of measurable AML that has progressed during or relapsed after prior therapy
  4. All acute toxic effects of any prior antitumor therapy resolved to Grade 1.
  5. Adequate hepatic profile.
  6. Adequate renal function.
  7. Adequate coagulation profile.
  8. Negative antiviral serology for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C.
  9. For female subjects of childbearing potential, a negative serum pregnancy test.
  10. For both male and female subjects, willingness to use adequate contraception.
  11. Willingness and ability of the subject to comply with study activities.
  12. Evidence of a personally signed informed consent document.

Exclusion criteria

  1. Leukemic blast cell count >50 × 10^9/L before the start of study therapy and despite the use hydroxyurea, cytarabine, and/or cyclophosphamide.
  2. Presence of known central nervous system (CNS) leukemia.
  3. Presence of another major cancer.
  4. Ongoing Grade >1 proliferative or nonproliferative retinopathy.
  5. Significant cardiovascular disease or ECG abnormalities.
  6. Significant gastrointestinal disease
  7. Uncontrolled ongoing infection.
  8. Pregnancy or breastfeeding.
  9. Major surgery within 4 weeks before the start of study therapy.
  10. Subject was a candidate for hematopoietic stem cell transplantation (HSCT).
  11. Ongoing severe graft-versus-house disease (GVHD) with Grade ≥2 serum bilirubin, Grade ≥3 skin involvement, or Grade ≥3 diarrhea at the start of study therapy.
  12. Prior solid organ transplantation.
  13. Ongoing immunosuppressive therapy other than corticosteroids.
  14. Use of a strong inhibitor or inducer of cytochrome P450 (CYP) 3A4.
  15. Use of a drug known to prolong the cardiac QT interval.
  16. Concurrent participation in another therapeutic or imaging clinical trial.
  17. Presence of a concomitant medical condition that (in the judgement of the investigator) interferes with the ability of the subject to participate in the study.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Sequential Assignment

Masking

None (Open label)

17 participants in 1 patient group

LAM-003
Experimental group
Description:
Open label LAM-003 at three sequentially increasing starting dose levels of 200, 300 and 450 mg.
Treatment:
Drug: Open Label LAM-003

Trial documents
2

Trial contacts and locations

6

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems